Citations

Showing 10 of 108152 citations.

Incidence and Outcomes of Neutropenia in Patients with Celiac Disease- a Consecutive Analysis of 1729 Patients
Vijayvargiya, Pooja , Gangat, Naseema , Litzow, Mark R. , Vijayvargiya, Priya , Patnaik, Mrinal M. , Go, Ronald S. , Murray, Joseph A.

Mayo Clinic

Blood | October 11, 2019 | Volume: 126 | Issue: 23 | Pages: 1013-1013

10.1182/blood.v126.23.1013.1013 Get It

Abstract Background : Celiac disease (gluten sensitive enteropathy) is a systemic disease with hematological manifestations including; iron deficiency anemia, vitamin B12 and folate deficiency, leukopenia/neutropenia, hyposplenism, venous thromboembolism, and the enteropathy associated T cell lymphoma (E-TCL). Leukopenia/neutropenia is rare, and can result from folate or copper deficiency, but in many cases remains idiopathic. The consequences of neutropenia and neutrophil responses to a gluten free diet are not well described. We carried out this study to assess the incidence and outcomes of neutropenia in patients with celiac disease. Methods : The Mayo clinic celiac disease database (n=1729) was retrospectively analyzed for all patients with a confirmed diagnosis of celiac disease that had leukopenia (<3.5 x10(9)/L) and/or neutropenia (<1.5 x 10(9)/L). The diagnosis of celiac disease was established by positive tissue transglutaminase antibodies (TTG) and confirmatory small bowel biopsy findings. Additional causes of neutropenia such as copper and folate deficiency, drugs, benign ethnic and cyclic neutropenia, chemotherapy, hematological malignancies, combined variable immunodeficiency (CVID), and autoimmune diseases were meticulously excluded. Data abstracted included demographics, temporal association with diagnosis, nadir counts, associated hematological findings, relationship with infections, the use and effect of G-CSF, response to gluten free diet and survival outcomes. Results: 21(1.2%) of 1729 cases screened had idiopathic-celiac related neutropenia; 17 (81%) Caucasian, 15 (48%) females. In 12(57%) patients the neutropenia preceded or occurred near the time of the diagnosis of celiac disease, while in 7 (33.3%) it occurred subsequently. In 2 cases the temporal association could not be established. The median age at diagnosis of celiac disease was 46 years (10-67) and the median follow up for this group was 41.7 months (0-207.3). At last follow up 1 (4.8%) death has been documented; 0 from infectious complications, with no cases of E-TCL. The median laboratory values at diagnosis of celiac disease were available in 11 (52%) patients and included; hemoglobin 12.9 g/dL (10.5-16.8), MCV 91.5 fl (79.6-102.8), WBC 3.2 x109/L (2.3-5.2), ANC 1.29x109/L (0.33-3.24), ALC 1.34x109/L (0.75-2.17), AMC 0.39x109/L (0.15-0.71), and platelet counts 225x109/L (168-711). Anti-granulocyte antibodies were assessed in 7 patients and were negative in all cases. None of these patients had coexistent hyposplenism and three cases of neutropenia that occurred in the setting of celiac disease and CVID were excluded. In 15 (71%) patients the neutropenia was incidentally detected during routine laboratory work and in 4 (19%) it came to light secondary to infections. Ten (48%) patients had recurrent infections (≥1) as documented by their providers, including 7 with sinopulmonary infections, 1 with urinary tract infections, and 1 with skin and soft tissue infections. Additional immunological assessments were not available in these patients. Three (14%) patients had an ANC <500 (significant neutropenia); of which 2 had recurrent sinopulmonary infections. The third patient remained largely asymptomatic. Two of the 3 patients received G-CSF support during infections and responded adequately (ANC improvement > 1 x 10(9)/L). The ANC in patients in this cohort did not correlate with severity of infections. Five (23%) of 21 patients had improvement in neutrophil counts after adopting a gluten free diet, while there was no response in 10 and data was unavailable in 6. The median time to ANC response was 14.5 months (10-15.3) and the median increment in ANC was 0.67 x 10(9)/L (0.48-0.98). Conclusions: Celiac disease associated neutropenia, especially significant neutropenia (ANC <500) is a rare occurrence (~1%). It can often pre-date the diagnosis of celiac disease or occur subsequently. It is potentially associated with an increased incidence of infections, with-out good correlation with the severity of neutropenia. Less than half the patients do seem to respond to a gluten free diet. G-CSF responses seem to be adequate and G-CSF can be used in the setting of severe infections. Disclosures No relevant conflicts of interest to declare.
Association of Genetic Risk of Obesity with Postoperative Complications Using Mendelian Randomization
Robinson, Jamie R. , Carroll, Robert J. , Bastarache, Lisa , Mou, Zongyang , Wei, Wei‐Qi, Connolly, John J. , Mentch, Frank , Sleiman, Patrick , Crane, Paul K. , Hebbring, Scott J. , Stanaway, Ian B. , Crosslin, David R. , Gordon, Allan , Rosenthal, Elisabeth A. , Petukhova, Lynn , Namjou, Bahram , Safarova, Maya , Walton, Nephi , Still, Christopher D. , Böttinger, Erwin P. , Loos, Ruth J. F. , Murphy, Shawn N. , Håkonarson, Håkon , Jarvik, Gail P. , Larson, Eric B. , Roden, Dan M. , Denny, Joshua C. , Safarova, Maya S, Hakonarson, Hakon , Denny, Joshua C , Jarvik, Gail P , Gordon, Adam S , Wei, Wei-Qi , Loos, Ruth J F , Connolly, John J , Chen, Qingxia , Carrell, David , Hayes, M. Geoffrey , Wei, Wei , Zhang, Ge, Jackson, Gretchen Purcell , Kullo, Iftikhar J. , Weng, Chunhua , Roden, Dan M.

Mayo Clinic

World Journal of Surgery | October 11, 2019 | Volume: 44 | Issue: 1 | Pages: 84-94

10.1007/s00268-019-05202-9 | PMID 31605180 Get It

AbstractBackgroundThe extent to which obesity and genetics determine postoperative complications is incompletely understood.MethodsWe performed a retrospective study using two population cohorts with electronic health record (EHR) data. The first included 736,726 adults with body mass index (BMI) recorded between 1990 and 2017 at Vanderbilt University Medical Center. The second cohort consisted of 65,174 individuals from 12 institutions contributing EHR and genome‐wide genotyping data to the Electronic Medical Records and Genomics (eMERGE) Network. Pairwise logistic regression analyses were used to measure the association of BMI categories with postoperative complications derived from International Classification of Disease‐9 codes, including postoperative infection, incisional hernia, and intestinal obstruction. A genetic risk score was constructed from 97 obesity‐risk single‐nucleotide polymorphisms for a Mendelian randomization study to determine the association of genetic risk of obesity on postoperative complications. Logistic regression analyses were adjusted for sex, age, site, and race/principal components.ResultsIndividuals with overweight or obese BMI (≥25 kg/m2) had increased risk of incisional hernia (odds ratio [OR] 1.7–5.5, p < 3.1 × 10−20), and people with obesity (BMI ≥ 30 kg/m2) had increased risk of postoperative infection (OR 1.2–2.3, p < 2.5 × 10−5). In the eMERGE cohort, genetically predicted BMI was associated with incisional hernia (OR 2.1 [95% CI 1.8–2.5], p = 1.4 × 10−6) and postoperative infection (OR 1.6 [95% CI 1.4–1.9], p = 3.1 × 10−6). Association findings were similar after limitation of the cohorts to those who underwent abdominal procedures.ConclusionsClinical and Mendelian randomization studies suggest that obesity, as measured by BMI, is associated with the development of postoperative incisional hernia and infection.
Natural History, Genetic Aberrations and Survival Distinguish Primary Plasma Cell Leukemia from Multiple Myeloma with Leukemic Transformation.
Tiedemann, Rodger E. , González-Paz, Natalia, Santana-Dávila, Rafael , Price-Troska, Tammy, Henderson, Kimberly J., Greipp, Philip R., Kyle, Robert A. , Lacy, Martha Q. , Chng, Wee Joo , Ketterling, Rhett P. , Gertz, Morie A. , Rajkumar, S. Vincent , Dispenzieri, Angela , Fonseca, Rafaël

Mayo Clinic

Blood | October 11, 2019 | Volume: 108 | Issue: 11 | Pages: 3587-3587

10.1182/blood.v108.11.3587.3587 Get It

Abstract Plasma cell leukemia (PCL) is an aggressive and rare hematological malignancy that can originate either as primary disease (pPCL) or as a leukemic transformation of multiple myeloma (MMLT). We report here on the clinical characteristics, survival and genetic studies of 80 patients with PCL treated at a single institution (including 41 with pPCL and 39 with MMLT) and make comparisons with 439 newly diagnosed cases of multiple myeloma (MM). From our results pPCL presents a decade earlier than MMLT (54.7 vs 65.3 years) and despite substantially poorer clinical and laboratory parameters at presentation (hepatomegaly 32% vs 11%, leukocytes 31.6 vs 20.9, β2M 8.5 vs 4.3) pPCL appears more responsive to conventional combination chemotherapy (VAD, VBMVP or VBAP) than MMLT and is associated with significantly longer survival (median 18.4 vs 3 months). Comparison of pPCL groups treated with combination chemotherapy (n=21) or with other regimens (40% MP, 10% Thal/Dex, 20% other, 30% none)(n=20) identifies no substantial pre-treatment differences between the groups although a higher proportion of patients who received combination chemotherapy subsequently proceeded to stem cell transplantation (30 vs 10%). Importantly, survival of pPCL patients treated initially with combination chemotherapy (median 13.9, mean 27.3 months) was significantly longer compared with patients who did not receive combination chemotherapy (median 5.2, mean 9.9 months)(p=0.035) with 2 long term survivors (> 7 years) in the chemotherapy group. By comparison, patients with MMLT received less active therapy for their leukemic disease than did patients with pPCL (21% VAD, VBMVP or VBAP; 18% MP). Treated MMLT patients showed selection bias for younger age (60.9 vs 66.4 years) and lack of bone disease (0 vs 65%)(p<0.01); however despite this, median survival was disappointingly short for MMLT patients in the treatment group and was not significantly improved compared with non-treated patients (2.3 vs 0.8 months)(p=0.34). Assessment of novel therapies in PCL is therefore urgently required. Karyotype analysis and targeted genetic studies demonstrate that IgH translocations are present with high frequency in both pPCL and MMLT (71 vs 86%) compared with MM (~50%). Notably, IgH translocation in pPCL is almost exclusively targeted at chromosome 11 (cyclin D1) belying its importance in establishing the phenotype. IgH translocation in MMLT is primarily to chromosome 11 [71%], but also targets chromosomes 4 (FGFR3/MMSET) [13%] and 16 (cMaf) [20%], recapitulating MM. Abnormalities of chromosomes 3,5,7,9,11,13,15 and 19 are present equally in all 3 disorders. Deletion of 17p13 (p53) shows strong selection pressure in the leukemias (pPCL 53.8%, MMLT 48.8%, MM 10.7%) and is complemented by p53 mutation (23%). Notably, pPCL tumors show lower rates of Ras mutation (12 vs 40%) and p14 (0 vs 31%) or p16 (25 vs 40%) promoter methylation than MMLT. Together these results therefore indicate that pPCL and MMLT are fundamentally different plasma cell disorders with distinctive biology, genetic abnormalities and treatment responses.
Measurement of Ejection Fraction by Cardiac Magnetic Resonance Imaging and Echocardiography to Monitor Doxorubicin-Induced Cardiotoxicity
Tak, Tahir , Jaekel, Camilla, Gharacholou, S. Michael , Dworak, Marshall , Marshall, Scott A., Jaekel, Camilla M, Gharacholou, Shahyar M, Dworak, Marshall W, Marshall, Scott A.

Mayo Clinic

International Journal of Angiology | October 11, 2019 | Volume: 29 | Issue: 01 | Pages: 045-051

10.1055/s-0039-1697921 | PMID 32132816 Get It

AbstractDoxorubicin is a standard treatment option for breast cancer, lymphoma, and leukemia, but its benefits are limited by its potential for cardiotoxicity. The primary objective of this study was to compare cardiac magnetic resonance imaging (CMRI) versus echocardiography (ECHO) to detect a reduction in left ventricular ejection function, suggestive of doxorubicin cardiotoxicity. We studied eligible patients who were 18 years or older, who had breast cancer or lymphoma, and who were offered treatment with doxorubicin with curative intent dosing of 240 to 300 mg/m2 body surface area between March 1, 2009 and October 31, 2013. Patients underwent baseline CMRI and ECHO. Both imaging studies were repeated after four cycles of treatment. Ejection fraction (EF) calculated by both methods was compared and analyzed with the inferential statistical Student's t test. Twenty-eight eligible patients were enrolled. Two patients stopped participating in the study before undergoing baseline CMRI; 26 patients underwent baseline ECHO and CMRI. Eight of those 26 patients declined posttreatment studies, so the final study population was 18 patients. There was a significant difference in EF pre- and posttreatment in the CMRI group (p = 0.009) versus the ECHO group that showed no significant differences in EF (p = NS). It appears that CMRI is superior to ECHO for detecting doxorubicin-induced reductions in cardiac systolic function. However, ECHO is less expensive and more convenient for patients because of its noninvasive character and bedside practicality. A larger study is needed to confirm these findings.
Study of the Subclonal Mutations in Primary Diffuse Large B-Cell Lymphoma
Asmann, Yan W. , Sarangi, Vivekananda , Ansell, Stephen M. , Nowakowski, Grzegorz S. , Novak, Anne J. , Wang, Chen , Maurer, Matthew J. , Feldman, Andrew L. , Habermann, Thomas M. , Slager, Susan L. , Link, Brian K. , Cerhan, James R.

Mayo Clinic

Blood | October 11, 2019 | Volume: 126 | Issue: 23 | Pages: 131-131

10.1182/blood.v126.23.131.131 Get It

Abstract Tumors arise and evolve by iterative steps of mutation, subclonal selection, and clonal expansion due to growth advantage of the fittest subclones and external mutation induction and selection pressure from radiation and drug therapies. Various studies have shown that greater clonal complexities in primary tumors are correlated with poor clinical outcome of tumor progression and/or drug resistance. Recently, we have reported that very few of the driver mutations, all of which were clonal, detected in primary diffuse large B-cell lymphoma (DLBCL) were associated with DLBCL outcome as measured by 24-month event-free survival (EFS24). In the current project, we identified and studied subclonal mutations in primary DLBCL tumors and assessed their associations with EFS24, as well as the role of activation-induced cytidine deaminase (AID) in genomic mutations occurred in DLBCL tumors. The detection of subclonal mutations is still a significant bioinformatics challenge. In addition, identification of clonal mutations in samples with lower tumor purities faces similar challenges due to the low concentration of reads supporting the mutant alleles. The current methods of somatic mutation calling are not sufficiently sensitive to identify the low concentration mutations in tumor DNA sequencing data. We implemented a bioinformatics workflow for low-concentration and subclonal mutation detection which is based on the positional read pile-up data and a back-fill approach (PUB). The pile-up files were first generated using the re-aligned and re-calibrated BAM files after read alignment using Burrows-Wheeler Aligner (BWA). The variant positions with alternative bases were annotated by attributes defined in the Variant Quality Score Recalibration (VQSR). PUB then used a boosting method and a generalized linear model (GLM) to train a model of 'good quality' variants using common variants from HapMap, and prioritized and called clonal and subclonal variants based on the trained model. The VQSR attributes related to alternative allele depth were less-weighed in order to call subclonal mutations. The somatic mutations were then identified by Fisher's Exact Test using sequencing depths of the reference and alternative alleles from paired tumor and germline sequencing data. The exome sequencing data of paired tumor and peripheral blood from 48 newly diagnosed DLBCL patients were analyzed using PUB. Thirty-six of the 48 patients achieved EFS24 with the other 12 patients experienced primary treatment failure. Most of the tumors studied had tumor purities between 40-70%. PUB identified substantially higher number of somatic mutations, both clonal and subclonal, compared to those detected using existing somatic callers. We observed that the prevalence of mutations in previously reported driver genes were higher using thresholds of mutation concentration ≥ 5% and Fisher's Exact Test p ≤ 0.05, including EZH2 (mutated in 26% of DLBCL tumors analyzed by PUB, compared to 12.7% as previously reported), MLL2 (72% vs. 31%), CD79B (22% vs. 14%), TNFRSF14 (36% vs. 20%), MEF2B (22% vs. 16.4%), CARD11 (46% vs. 21.8%), and MYD88 (18% vs. 11%). In addition, other genes involved tumorigenesis that have not been previously linked to DLBCL also harbored both clonal and subclonal mutations with substantial prevalence, including FGFR3 (12%), KIT (24%), and ATM (28%). Furthermore, association of genes displaying clonal and subclonal mutations with EFS24 identified potential biomarkers for DLBCL outcome. Among these, two genes EPGN and ASTE are involved in epithelial growth factor receptor signaling and had association p values of 0.0001 and 0.0016, respectively. The oncogene MAFB was also associated with EFS24 (p= 0.0016). We searched for AID induced mutations among all identified variant positions and concluded that there was no evidence of AID site enrichments compared to a simulated data set. In summary, we developed and applied a sensitive bioinformatics pipeline for the identification of both clonal and low concentration somatic mutations in primary DLBCL exome sequencing data which further revealed the clonal complexity of the primary DLBCL tumors. Several of the genes were identified as potential biomarkers for DLBCL outcome. Disclosures Maurer: Kite Pharma: Research Funding. Ansell:Bristol-Myers Squibb: Research Funding; Celldex: Research Funding. Link:Genentech: Consultancy, Research Funding; Kite Pharma: Research Funding. Cerhan:Kite Pharma: Research Funding.
Caspases Mediate Tumor Necrosis Factor-–Induced Neutrophil Apoptosis and Downregulation of Reactive Oxygen Production
Yamashita, Kouhei , Kobayashi, Susumu , Hirata, Hirokazu, Mesner, Peter W., Yonehara, Shin , Yamamoto, Kokichi, Uchiyama, Takashi , Sasada, Masataka, Takahashi, Atsushi, Kaufmann, Scott H.

Mayo Clinic

Blood | October 11, 2019 | Volume: 93 | Issue: 2 | Pages: 674-685

10.1182/blood.v93.2.674.402k26_674_685 Get It

Tumor necrosis factor- (TNF-) exerts two separate effects on neutrophils, stimulating effector functions while simultaneously inducing apoptosis. We examined here the involvement of caspases in neutrophil apoptosis and the effect of TNF-–induced apoptosis on reactive oxygen production. Immunoblotting and affinity labeling showed activation of caspase-8, caspase-3, and a caspase with a large subunit of 18 kD (T18) in TNF-–treated neutrophils. Active caspase-6 and -7 were not detectable in this cell type. Caspase-8 activated caspase-3 and T18 in neutrophil cytoplasmic extracts. zVAD-fmk blocked neutrophil apoptosis, in parallel with the inhibition of caspase activation. TNF-–induced caspase activation was accompanied by a decrease in the ability of neutrophils to release superoxide anion. Conversely, TNF- treatment in the presence of zVAD-fmk caused a prolonged augmentation of superoxide release. Granulocyte-macrophage colony-stimulating factor inhibited TNF-–induced caspase activation and apoptosis, while reversing the diminution in superoxide release. These observations not only suggest that a caspase cascade mediates apoptotic events and downregulates oxygen radical production in TNF-–treated neutrophils, but also raise the possibility that suppression of caspase activation with enhanced proinflammatory actions of TNF- may underlie the pathogenesis of inflammatory diseases.
Day 15 Natural Killer (NK) Cell Recovery Predicts Progression Free Survival after Autologous Stem Cell Transplantation in Non-Hodgkin’s Lymphoma.
Nevala, Wendy K. , Uhl, Cindy B., Morice, William G. , Porrata, Luis F. , Siddiqui, Mustaqeem , Markovic, Svetomir N. , Morice, William George

Mayo Clinic

Blood | October 11, 2019 | Volume: 108 | Issue: 11 | Pages: 2914-2914

10.1182/blood.v108.11.2914.2914 Get It

Abstract The peripheral blood absolute lymphocyte count (ALC) on day 15 after autologous stem cell transplantation (ASCT) has been shown to be an independent predictor for overall survival (OS) for many malignancies including acute myelogenous leukemia (AML), breast cancer, multiple myeloma (MM), primary systemic amyloidosis, and Hodgkin’s and non-Hodgkin’s lymphoma (NHL). However, due to the retrospective nature of previous studies, the peripheral blood lymphocyte subpopulations that predict survival are unknown. To prospectively correlate peripheral blood lymphocyte subpopulations after ASCT and progression free survival, peripheral blood lymphocytes collected from patients before and on day 15 after ASCT were analyzed by four color flow cytometry for CD3, CD4, CD8, CD16, CD 19, and CD56. Patients were then dichotomized into two groups: patients achieving normal numbers of lymphocyte subset (i.e. CD4, CD8, CD19, CD16/56) count versus those who did not. Progression free survival was then analyzed by the Kaplan-Mier method. In our cohort of 14 patients, 9 were male and 5 were female. Nine patients were diagnosed with diffuse large cell B cell lymphoma, two with mantle cell, two with follicular, and one with peripheral T cell lymphoma. On presentation, one patient had stage I, four patients had stage II, four had stage III, and five patients had stage IV disease. The median age at ASCT was 53 years (range: 26–70). The preliminary data from this ongoing prospective study of 14 patients shows that on day 15 after ASCT, 4/14 (29%) of patients achieved a normal CD3 count (median 321, range: 69–2069 cells/ml) 3/14 (21%) achieved a normal CD4 count (median 206, range: 31–1091 cells/ml), 6/14 (43%) achieved a normal CD 8 count (median 88.5, range: 13–813 cells/ml) 1/14 (7%) achieved a normal CD19 count (median 2, range:0–227 cells/ml), and 8/14 (57%) achieved a normal CD16/56 count (median 85.5, range: 10–744 cells/ml). The median follow-up was 12 months (range: 3–45 months). On univariate analysis, patients achieving an absolute NK cell count of ≥ 80 cells/μ on day 15 had significantly improved progression free survival compared to those who did not (not reached vs 3 months, p<0.006, respectively). Similar analysis evaluating the absolute CD3, CD4, CD8, and CD 19 count was not significant (p=0.1, p=0.258, p= 0.06, and p=0.55, respectively). To our knowledge, this is the first report detailing the critical role of NK cell immune reconstitution after ASCT in progression free survival. Figure Figure
TG101209, a Selective JAK2 Kinase Inhibitor, Suppresses Endogenous and Cytokine-Supported Colony Formation from Hematopoietic Progenitors Carrying JAK2V617F or MPLW515K/L Mutations.
Pardanani, Animesh , Hood, John, Finke, Christy M. , Mak, Chi Ching, Zhu, Hong , Söll, Richard, Tefferi, Ayalew , Lasho, Terra L. , Noronha, Glenn , Mesa, Ruben A.

Mayo Clinic

Blood | October 11, 2019 | Volume: 108 | Issue: 11 | Pages: 2680-2680

10.1182/blood.v108.11.2680.2680 Get It

Abstract Background: acquisition of somatic mutations including JAK2V617F or MPLW515L/K results in constitutive activation of JAK-STAT signaling that commonly characterizes myeloproliferative disorders (MPD). JAK2 is the central signaling mediator for most hematopoietic cytokines in this signaling pathway. Hypothesis: small molecule JAK2 inhibitors may have a therapeutic role in MPD regardless of JAK2 mutation status. Methods: We studied effects of the JAK2 inhibitor, TG101209, in a cell-free kinase assay, relevant cell lines, an in vivo phosphorylation assay, and primary cells from MPD patients carrying JAK2V617F or MPLW515L/K mutations. Results: in a cell-free kinase assay, TG101209 inhibited JAK2 potently (IC50=6nM) and displayed selectivity relative to JAK3, ABL, and VEGFR2 kinases (IC50=170nM, 820nM, and 150nM, respectively). In cell proliferation assays, TG101209 inhibited JAK2-expressing Ba/F3 cells (IC50=280nM) and JAK2V617F-homozygous human erythroleukemia (HEL) cells (IC50=300nM), but not BCR-ABL-carrying K562 cells (IC50>2μM). At 24 hours, TG101209 (600nM) induced apoptosis of HEL cells but not K562 cells (40% and 5%, respectively). SCID mice injected intravenously with Ba/F3-JAK2V617F cells developed significant disease burden including massive splenomegaly due to tumor infiltration (day 12). We observed marked decrease in STAT5 phosphorylation in splenic tumors 5 hours after administration of 2 oral doses of TG101209 (50 mg/kg) in this in vivo model. Based on the above data, we plated patient-derived CD34+ cells in methylcellulose (0nM, 300nM, and 600nM TG101209) with and without cytokines. We studied 2 controls and 9 MPD patients: PV=5 (all JAK2V617F+) and AMM=4 (3 were MPLW515L/K+) for colony number, colony size, and colony mutation burden, under each assay condition. TG101209 inhibited overall colony growth from MPD patients (IC50=300–600nM), and it preferentially suppressed growth of mutant colonies relative to wild type in both of 2 MPLW515K+ patients (AMM1 and AMM2) and in 3 of 5 JAK2V617+ patients (PV1-PV3) (Table). Conclusions: TG101209 potently inhibits cell growth that is dependent on constitutive JAK-STAT signaling. Furthermore, for MPD patient-derived cells, TG101209 preferentially suppresses growth of progenitors carrying JAK-activating mutations (MPLW515K>JAK2V617F>MPLW515L). Hence, our data supports the strategy of targeting aberrant JAK-pathway signaling in MPD as a viable therapeutic approach. Patient Mutation IC50 (nM) No Drug (% colonies mutation-positive) TG101209 (% colonies mutation-positive) Erythroid Myeloid Erythroid Myeloid Erythroid Myeloid Normal WT 1000 600 n/a PV1 JAK2V617F ~600 300–600 82 90 36 70 PV2 JAK2V617F ~300 70 55 60 20 PV3 JAK2V617F NA 20 30 30 0 PV4 JAK2V617F >600 ~600 7 10 17 10 PV5 JAK2V617F ~300 300–600 64 92 82 100 AMM1 MPLW515K <300 ~300 100 90 0 20 AMM2 MPLW515K 300–600 ~300 100 90 25 36 AMM3 MPLW515L 300–600 300–600 100 100 92 90 AMM4 WT >600 300–600 n/a
Transplantation without Growth Factor. Engraftment Kinetics Following Stem Cell Transplantation for Primary Systemic Amyloidosis.
Lacy, Martha Q. , Hayman, Suzanne R. , Kumar, Shaji , Gastineau, Dennis A. , Gertz, Morie A. , Dispenzieri, Angela

Mayo Clinic

Blood | October 11, 2019 | Volume: 108 | Issue: 11 | Pages: 2956-2956

10.1182/blood.v108.11.2956.2956 Get It

INTRODUCTION The use of growth factors filgrastim and sargramostim are associated with often dramatic degrees of fluid retention in patients with amyloidosis who have coexistent cardiac involvement or nephrotic syndrome. Significant degrees of fluid retention can complicate the post transplant management of patients with AL receiving high dose chemotherapy. We report outcomes in a cohort of amyloidosis patients who received no growth factor support post transplant. PATIENTS AND METHODS 283 consecutive patients seen for stem cell transplant are included in this cohort. In order to be considered evaluable for engraftment the patient must have survived for 30 days or was excluded from analysis. All patients had biopsy verified AL. Patients also had to have visceral organ dysfunction in order to be eligible for stem cell transplant with a minimum of one visceral organ involved. RESULTS Among 283 patients transplanted, 244 were evaluable for engraftment. There were 145 men (59%). Renal involvement was present in 163 (67%), cardiac involvement by echocardiography in 47%, hepatic involvement in 16%, and peripheral nerve involvement in 11%. The median age was 56.6 years (range 33–73). The median time from diagnosis of amyloidosis to stem cell transplantation was 4.2 months. A neutrophil count of 500/uL was achieved in 50%, 75%, and 90% of the total group at 14, 16, and 22 days respectively (figure 1). A platelet count of 20,000/uL was achieved in 50%, 75%, and 90% of patients at 14, 19, and 28 days respectively (figure 2). A platelet count of 50,000/uL was achieved in 50%, 75%, and 90% of patients at 18, 28, and 52 days respectively. The median time spent in the hospital for the entire cohort 9 days. 46 of the patients (19%) completed the entire procedure as an outpatient. 75% of patients were discharged within 18 days and 90% were discharged within 32 days. 137 patients were blood culture negative throughout the entire procedure (56%). A blood culture was positive in the remaining 107 patients. 68 of these 107 contained a culture for Staph. coagulase negative. 39 (16%) had bacteremia associated with other organisms. CONCLUSION Transplantation of patients with amyloidosis without using growth factor is feasible. The median time to achieve neutrophil and platelet counts of 500 and 20,000/uL respectively is 14 days. It is reasonable to withhold growth factor from AL patients undergoing stem cell transplantation. Figure Figure Figure Figure
Analysis of Serum Ferritin Levels As a Diagnostic Criteria for Hemophagocytic Lymphohistiocytosis (HLH) in Hospitalized Adult Patients
Pham, Anthony , O’Byrne, Megan M., Kapoor, Prashant , Abraham, Roshini S. , Wolanskyj, Alexandra P., Shah, Meera , Go, Ronald S. , Parikh, Sameer A.

Mayo Clinic

Blood | October 11, 2019 | Volume: 126 | Issue: 23 | Pages: 1014-1014

10.1182/blood.v126.23.1014.1014 Get It

Abstract INTRODUCTION: Hemophagocytic lymphohistiocytosis (HLH) is a rare disorder caused by the pathologic activation of the immune system. In children, either a molecular diagnosis consistent with HLH or five out of the following eight criteria are considered necessary for a diagnosis of HLH (HLH-04 criteria): 1) fever; 2) splenomegaly; 3) cytopenia in two or more cell lines; 4) hypertriglyceridemia (≥265 mg/dL) or hypofibrinogenemia (≤150 mg/dL); 5) hemophagocytosis in the bone marrow, spleen, or lymph nodes; 6) hyperferritinemia (≥500 mcg/L); 7) impaired NK cell function; and 8) elevated soluble CD25 (sCD25). These criteria have been extrapolated to diagnose HLH in adults; however, it's unclear if these same criteria are applicable in the adult population. METHODS: We reviewed the Mayo Clinic electronic medical record for all adult (≥18 years) hospitalized patients with an admission serum ferritin of ≥500 mcg/L from January 2012 through December 2014. Patients' charts were reviewed and those who met the HLH-04 criteria were considered to have HLH. For the remainder of the patients, the etiology for hyperferritinemia was determined based on chart review and discharge diagnoses. Logistic regression models were used to assess the ability of these values in predicting a diagnosis of HLH. The Mayo Clinic IRB approved this study. RESULTS: We identified 1,329 patients with a serum ferritin ≥500 mcg/L. Of these, HLH was diagnosed in 28 (2.1%) patients (malignancy-associated HLH in 11 patients, infection-associated HLH in 4 patients, autoimmune-associated HLH in 7 patients, and idiopathic HLH in 6 patients). Table 1 describes the etiology of hyperferritinemia in the remaining 1,301 patients. In contrast to pediatric hospitalized patients (Allen, Pediatr Blood Cancer, 2008), adults are more likely to have malignancy (28.1% vs 7%; p<0.05); bacterial infection (21% vs. 13%; p=0.001); liver disease (9.9% vs. 2.7%; p<0.05); and cardiac disease (7.2% vs. 1.5%; p=0.0001) as the etiology of hyperferritinemia during their hospitalization. Among all patients in the study, the following variables were associated with higher odds of having HLH compared to hyperferritinemia due to an alternate cause: elevated ferritin (odds ratio [OR] 35.97, p<0.01); thrombocytopenia (OR 15.22, p<0.01), cytopenias defined by HLH-04 criteria (OR 8.04, p<0.01); elevated admission serum bilirubin (OR 1.05, p=0.02); and peak serum bilirubin (OR 1.05, p<0.01). After stepwise selection in multivariate analysis, serum ferritin ≥2,600 mcg/L and platelets ≤100 x 109/L were independently associated with HLH diagnosis (OR 24.9 and 7.8 respectively; p<0.01 for both). The area under the curve (AUC or c-statistic) ranges from 0.5 for no ability to discriminate, to 1.0 for perfect discrimination; this model has an AUC of 0.91, which shows very good discrimination between cases and controls. An adult hospitalized patient with a combination of serum ferritin ≥2,600 mcg/L and platelets ≤100x109/L predicts a ~200 fold increased likelihood of being diagnosed with HLH as compared to hospitalized adult meeting neither of these criteria (Figures 1 and 2). CONCLUSION: In contrast to hospitalized pediatric patients, the etiology of hyperferritinemia in adults is more likely to be malignancy, bacterial infection, liver disease, and cardiac disease. We conclude that a combination of serum ferritin ≥2,600 mcg/L and platelet count ≤100 x 109/L can be used as screening criteria to help identify adult patients most likely to have HLH. The traditional 5/8 criteria to diagnose HLH in pediatric patients do not appear necessary for establishing a diagnosis of HLH in adult patients. These observations need replication in an independent data set prior to broader applicability. Table 1.Patients with ferritin > 500 mcg/L with underlying cause for elevation.Number Diagnosed (%)Cardiac Disease95 (7.2%)Liver Disease131 (9.9%)Renal Disease87 (6.6%)Infectious343 (25.8%)Malignancy373 (28.1%)Autoimmune118 (8.9%)Solid Organ Transplant34 (2.6%)Stem Cell Transplant16 (1.2%)Bone Marrow Failure9 (0.7%)Shock39 (2.9%)Idiopathic53 (4.0%)Hemoglobinopathies3 (0.2%) Figure 1. ROC curve for the multivariable model with ferritin > 2,600 (yes/no) and platelets below 100,000 (yes/no) in the model with a very good discrimination c-statistic of 0.91. Figure 1. ROC curve for the multivariable model with ferritin > 2,600 (yes/no) and platelets below 100,000 (yes/no) in the model with a very good discrimination c-statistic of 0.91. Figure 2. Figure 2. Disclosures No relevant conflicts of interest to declare.